Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

Eric O Aboagye; Fiona J Gilbert; Ian N Fleming; Ambros J Beer; Vincent J Cunningham; Paul K Marsden; Dimitris Visvikis; Antony D Gee; Ashley M Groves; Laura M Kenny; Gary J Cook; Paul E Kinahan; Melvyn Myers; Larry Clarke; Experimental Cancer Medicine Centre 13 Imaging Network Group

doi:10.1007/s00330-011-2311-3

Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

Eric O Aboagye, Fiona J Gilbert, Ian N Fleming, Ambros J Beer, Vincent J Cunningham, Paul K Marsden, Dimitris Visvikis, Antony D Gee, Ashley M Groves, Laura M Kenny, Gary J Cook, Paul E Kinahan, Melvyn Myers, Larry Clarke, Experimental Cancer Medicine Centre 13 Imaging Network Group

Research output: Contribution to journal › Article › peer-review

15 Citations (Scopus)

Abstract

The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and radiotracers range from direct physiological functional tracers like [(15)O]-water to macromolecular probes targeting integrin receptors expressed on neovasculature. Finally we make recommendations on ways to incorporate such measurements of tumour vascularity into early clinical trials of novel therapeutics.

Key Points
• [ ( 15 ) O]-water is the gold standard for blood flow/tissue perfusion with PET
• In some instances dynamic [ ( 18 ) F]-FDG uptake may be used to estimate perfusion
• Radiopharmaceuticals that target integrins are now being evaluated for measuring tumour vascularity.

Original language	English
Pages (from-to)	1465-1478
Number of pages	14
Journal	European Radiology
Volume	22
Issue number	7
Early online date	4 Apr 2012
DOIs	https://doi.org/10.1007/s00330-011-2311-3
Publication status	Published - 1 Jul 2012

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00330-011-2311-3

Cite this

Aboagye, E. O., Gilbert, F. J., Fleming, I. N., Beer, A. J., Cunningham, V. J., Marsden, P. K., Visvikis, D., Gee, A. D., Groves, A. M., Kenny, L. M., Cook, G. J., Kinahan, P. E., Myers, M., Clarke, L., & Experimental Cancer Medicine Centre 13 Imaging Network Group (2012). Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials. European Radiology, 22(7), 1465-1478. https://doi.org/10.1007/s00330-011-2311-3

Aboagye, EO, Gilbert, FJ, Fleming, IN, Beer, AJ, Cunningham, VJ, Marsden, PK, Visvikis, D, Gee, AD, Groves, AM, Kenny, LM, Cook, GJ, Kinahan, PE, Myers, M, Clarke, L & Experimental Cancer Medicine Centre 13 Imaging Network Group 2012, 'Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials', European Radiology, vol. 22, no. 7, pp. 1465-1478. https://doi.org/10.1007/s00330-011-2311-3

@article{6c57fa5197dd40a5be09824c51938533,

title = "Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials",

abstract = "The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and radiotracers range from direct physiological functional tracers like [(15)O]-water to macromolecular probes targeting integrin receptors expressed on neovasculature. Finally we make recommendations on ways to incorporate such measurements of tumour vascularity into early clinical trials of novel therapeutics. Key Points • [ ( 15 ) O]-water is the gold standard for blood flow/tissue perfusion with PET • In some instances dynamic [ ( 18 ) F]-FDG uptake may be used to estimate perfusion • Radiopharmaceuticals that target integrins are now being evaluated for measuring tumour vascularity.",

author = "Aboagye, {Eric O} and Gilbert, {Fiona J} and Fleming, {Ian N} and Beer, {Ambros J} and Cunningham, {Vincent J} and Marsden, {Paul K} and Dimitris Visvikis and Gee, {Antony D} and Groves, {Ashley M} and Kenny, {Laura M} and Cook, {Gary J} and Kinahan, {Paul E} and Melvyn Myers and Larry Clarke and {Experimental Cancer Medicine Centre 13 Imaging Network Group}",

year = "2012",

month = jul,

day = "1",

doi = "10.1007/s00330-011-2311-3",

language = "English",

volume = "22",

pages = "1465--1478",

journal = "European Radiology",

issn = "0938-7994",

publisher = "Springer Verlag",

number = "7",

}

TY - JOUR

T1 - Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

AU - Aboagye, Eric O

AU - Gilbert, Fiona J

AU - Fleming, Ian N

AU - Beer, Ambros J

AU - Cunningham, Vincent J

AU - Marsden, Paul K

AU - Visvikis, Dimitris

AU - Gee, Antony D

AU - Groves, Ashley M

AU - Kenny, Laura M

AU - Cook, Gary J

AU - Kinahan, Paul E

AU - Myers, Melvyn

AU - Clarke, Larry

AU - Experimental Cancer Medicine Centre 13 Imaging Network Group

PY - 2012/7/1

Y1 - 2012/7/1

N2 - The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and radiotracers range from direct physiological functional tracers like [(15)O]-water to macromolecular probes targeting integrin receptors expressed on neovasculature. Finally we make recommendations on ways to incorporate such measurements of tumour vascularity into early clinical trials of novel therapeutics. Key Points • [ ( 15 ) O]-water is the gold standard for blood flow/tissue perfusion with PET • In some instances dynamic [ ( 18 ) F]-FDG uptake may be used to estimate perfusion • Radiopharmaceuticals that target integrins are now being evaluated for measuring tumour vascularity.

AB - The evaluation of drug pharmacodynamics and early tumour response are integral to current clinical trials of novel cancer therapeutics to explain or predict long term clinical benefit or to confirm dose selection. Tumour vascularity assessment by positron emission tomography could be viewed as a generic pharmacodynamic endpoint or tool for monitoring response to treatment. This review discusses methods for semi-quantitative and quantitative assessment of tumour vascularity. The radioligands and radiotracers range from direct physiological functional tracers like [(15)O]-water to macromolecular probes targeting integrin receptors expressed on neovasculature. Finally we make recommendations on ways to incorporate such measurements of tumour vascularity into early clinical trials of novel therapeutics. Key Points • [ ( 15 ) O]-water is the gold standard for blood flow/tissue perfusion with PET • In some instances dynamic [ ( 18 ) F]-FDG uptake may be used to estimate perfusion • Radiopharmaceuticals that target integrins are now being evaluated for measuring tumour vascularity.

U2 - 10.1007/s00330-011-2311-3

DO - 10.1007/s00330-011-2311-3

M3 - Article

C2 - 22476502

SN - 0938-7994

VL - 22

SP - 1465

EP - 1478

JO - European Radiology

JF - European Radiology

IS - 7

ER -

Recommendations for measurement of tumour vascularity with positron emission tomography in early phase clinical trials

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this